NPHLA Tracker · GLP-1 & obesity drug pipeline (ClinicalTrials.gov)
GLP-1 & Obesity Drug Pipeline
Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 181
- Changed in 7 days
- 4
- Latest record
- Jurisdiction
- International / multiple
Records
181 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| A Study of BGM0504 in Participants With Type 2 DiabetesNCT06716216Changed in the last 7 days Status changed from “Active, not recruiting” to “Completed” · Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC; Drug: Semaglutide Administered SC | Completed | Phase 3 | BrightGene Bio-Medical Technology Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06716216 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Conditions: Type 2 Diabetes. Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06297603 (opens in a new tab)Primary source | System checked NPHLA updated |
| AMBITION 3: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothNCT07931573Conditions: Type 2 Diabetes. Interventions: Zenagamtide; Semaglutide; Placebo | Not yet recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931573 (opens in a new tab)Primary source | System checked NPHLA updated |
| AMBITION4: A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothNCT07931599Conditions: Diabetes Mellitus, Type 2. Interventions: Zenagamtide; Semaglutide; Placebo zenagamtide; Placebo semaglutide | Not yet recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931599 (opens in a new tab)Primary source | System checked NPHLA updated |
| SURMOUNT-1: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)NCT07481747Conditions: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. Interventions: Tirzepatide; Placebo; Reduced-calorie diet | Recruiting | Phase 3 | Hudson Biotech | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07481747 (opens in a new tab)Primary source | System checked NPHLA updated |
| COURAGE: A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098Conditions: Obesity. Interventions: Trevogrumab-Part A; Trevogrumab-Part B and Part C; Garetosmab; Semaglutide; Matching Placebo-Part A; Matching Placebo-T… | Completed | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06299098 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or OverweightNCT07932925Conditions: Urinary Incontinence, Stress; Overweight and/or Obesity. Interventions: Berobenatide; Placebo | Not yet recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07932925 (opens in a new tab)Primary source | System checked NPHLA updated |
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyNCT07642635Conditions: Duchenne Muscular Dystrophy (DMD). Interventions: Semaglutide (Rybelsus®); Placebo | Recruiting | Phase 1 / Phase 2 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07642635 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846Conditions: Obesity. Interventions: ALN-2232; Placebo; Tirzepatide | Recruiting | Phase 1 / Phase 2 | Alnylam Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07463846 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentNCT00739362Conditions: Electric Stimulation Therapy; Obesity; Weight Loss; Eating. Interventions: Transcranial Direct Current Stimulation (TDCS); Sham/no-stimulation | Active, not recruiting | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT00739362 (opens in a new tab)Primary source | System checked NPHLA updated |
| SURMOUNT-MMO: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512Conditions: Obesity; Overweight. Interventions: Tirzepatide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05556512 (opens in a new tab)Primary source | System checked NPHLA updated |
| TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792Changed in the last 7 days Status changed from “Not yet recruiting” to “Recruiting” · Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC) | Recruiting | Phase 2 / Phase 3 | yifang zhu | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07734792 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872Changed in the last 7 days Status changed from “Active, not recruiting” to “Recruiting” · Conditions: Type 2 Diabetes Mellitus. Interventions: Tifeglipron; Semaglutide; Placebo | Recruiting | Phase 2 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07112872 (opens in a new tab)Primary source | System checked NPHLA updated |
| GZBF: Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447Conditions: Obesity. Interventions: Retatrutide (LY3437943); Placebo; Standardized diet and physical activity counseling throughout the study. | Recruiting | Phase 2 | Hudson Biotech | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07467447 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)NCT03407079Conditions: Healthy Volunteers; Overweight. Interventions: Sucralose; Placebo | Recruiting | Phase 2 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03407079 (opens in a new tab)Primary source | System checked NPHLA updated |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Interventions: Survodutide; Placebo matching survodutide | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850063 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864Conditions: Obesity. Interventions: survodutide; Placebo | Completed | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06077864 (opens in a new tab)Primary source | System checked NPHLA updated |
| Optimum 2: A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusNCT06778967Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: GZR18; semaglutide | Completed | Phase 3 | Gan & Lee Pharmaceuticals. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06778967 (opens in a new tab)Primary source | System checked NPHLA updated |
| GZR18-BWM-303: Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossNCT07292441Conditions: Overweight or Obesity. Interventions: GZR18 injection; Placebo | Completed | Phase 3 | Gan & Lee Pharmaceuticals. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07292441 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityNCT07929298Conditions: Overweight , Obesity; Weight Management. Interventions: ecnoglutide tablet; placebo with matching dosage | Not yet recruiting | Phase 2 | Hangzhou Sciwind Biosciences Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07929298 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityNCT07830329Conditions: Hidradenitis Suppurativa. Interventions: Olatorepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07830329 (opens in a new tab)Primary source | System checked NPHLA updated |
| GRABS-0: GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialNCT06162715Conditions: Severe Obesity; Obesity; BMI Greater Than 30. Interventions: Tirzepatide; Standard of Care post-gastric bypass | Active, not recruiting | Phase 2 / Phase 3 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06162715 (opens in a new tab)Primary source | System checked NPHLA updated |
| AMAZE 8: AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: NNC0487-0111; Semaglutide; Placebo (matched to NNC0487-0111); Placebo (matched to semaglutide) | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07400107 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-8: A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719Conditions: Obesity; Overweight. Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07232719 (opens in a new tab)Primary source | System checked NPHLA updated |
| Enith1: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045Conditions: Obesity or Overweight. Interventions: Placebo; Enicepatide | Recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07351045 (opens in a new tab)Primary source | System checked NPHLA updated |
| Enith2: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058Conditions: Obesity or Overweight; Type 2 Diabetes Mellitus. Interventions: Placebo; Enicepatide | Recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07351058 (opens in a new tab)Primary source | System checked NPHLA updated |
| Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusNCT07775404Conditions: Obesity; Overweight. Interventions: Elecoglipron; Placebo | Recruiting | Phase 3 | AstraZeneca | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07775404 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151Changed in the last 7 days Results first posted on ClinicalTrials.gov (2026-11-09) · Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo | Completed | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05936151 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes MellitusNCT07923357Conditions: Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes; T2DM. Interventions: SAL0150 dose 1; SAL0150 dose 2; SAL0150 dose 2; SAL0150 dose 3; SAL0150 dose 3; Placebo; Semaglutide inject 1.0 mg | Not yet recruiting | Phase 2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07923357 (opens in a new tab)Primary source | System checked NPHLA updated |
| VITAL-H: Validation & Intervention Testing for Aging, Longevity and HealthspanNCT07923630Conditions: Aging; Functional Decline. Interventions: Dapagliflozin 10Mg Oral Tablet; Semaglutide oral; Placebo | Not yet recruiting | Phase 2 | The University of Texas Health Science Center at San Antonio | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07923630 (opens in a new tab)Primary source | System checked NPHLA updated |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseNCT07651319Conditions: Alzheimer Dementia (AD). Interventions: IL-2 (Aldesleukin); Semaglutide Plus IL-2; Placebo | Recruiting | Phase 1 / Phase 2 | The Methodist Hospital Research Institute | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07651319 (opens in a new tab)Primary source | System checked NPHLA updated |
| QUEST: Lifestyle Counseling and Medication for Adolescent Weight ManagementNCT04873245Conditions: Obesity, Childhood. Interventions: Intensive Behavioral Program; Semaglutide and Behavioral Program | Completed | Phase 2 | University of Minnesota | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04873245 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399Conditions: Obesity or Overweight. Interventions: Maridebart Cafraglutide | Recruiting | Phase 3 | Amgen | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07575399 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Conditions: Overweight or Obesity. Interventions: Olatorepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07685808 (opens in a new tab)Primary source | System checked NPHLA updated |
| T2DM: UBT251 Injection Phase II (Type 2 Diabetes Mellitus) StudyNCT07163624Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: UBT251 Injection 2.0 mg and UBT251 Injection Placebo; UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo;… | Completed | Phase 2 | The United Bio-Technology (Hengqin) Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07163624 (opens in a new tab)Primary source | System checked NPHLA updated |
| SPOT-DM: Semaglutide for the Prevention Of Post-Transplant Diabetes MellitusNCT06913023Conditions: Kidney Transplant Recipient. Interventions: Semaglutide 0.25 mg; Semaglutide 0.5 mg; Semaglutide 1.0 mg; Semaglutide 1.7mg subcutaneous; Semaglutide 2.4 MG/0.75 ML… | Not yet recruiting | Phase 2 / Phase 3 | University Health Network, Toronto | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06913023 (opens in a new tab)Primary source | System checked NPHLA updated |
| REDEFINE: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNCT07919405Conditions: Hypertension; Obesity. Interventions: CagriSema; Semaglutide; Cagrilintide; Placebo | Not yet recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07919405 (opens in a new tab)Primary source | System checked NPHLA updated |
| Enith-MACE: A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular DiseaseNCT07918846Conditions: Overweight; Obesity; Cardiovascular Disease. Interventions: Enicepatide; Placebo | Not yet recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07918846 (opens in a new tab)Primary source | System checked NPHLA updated |
| VESPER-3: A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightNCT06973720Conditions: Obesity; Overweight or Obesity. Interventions: MET097; Placebo | Completed | Phase 2 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06973720 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)NCT07919678Conditions: Obesity; Overweight; Osteoarthritis of the Knee. Interventions: Berobenatide; Placebo | Recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07919678 (opens in a new tab)Primary source | System checked NPHLA updated |
| MARITIME-T2D-3: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNCT07866066Conditions: Diabetes Mellitus, Type 2. Interventions: Maridebart cafraglutide; Semaglutide | Recruiting | Phase 3 | Amgen | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07866066 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416Conditions: Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM). Interventions: Enicepatide; Placebo | Recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07670416 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Conditions: Diabetes Mellitus, Type 2. Interventions: Orforglipron; Dulaglutide | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07668336 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07794579 (opens in a new tab)Primary source | System checked NPHLA updated |
| SOLIS-1: A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932Conditions: Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseas…. Interventions: PF-08653945; PF-08653944; Placebo | Active, not recruiting | Phase 2 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07575932 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Interventions: Semaglutide; Berobenatide; Tirzepatide | Recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07845500 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)NCT07915609Conditions: Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2. Interventions: Berobenatide; Placebo | Recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07915609 (opens in a new tab)Primary source | System checked NPHLA updated |
| GALACTUS: Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)NCT07295223Conditions: Acute Myocardial Infarction With ST Elevation. Interventions: Dapagliflozin 10 MG Oral Tablet; Semaglutide (Rybelsus®) | Completed | Phase 3 | Instituto Mexicano del Seguro Social | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07295223 (opens in a new tab)Primary source | System checked NPHLA updated |
| Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthNCT06975111Conditions: Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular. Interventions: Metformin; semaglutide; Anti-hypertensives; Lipid Lowering Medication; Life style intervention; Fezolinetant; Hormonal… | Recruiting | Phase 2 / Phase 3 | University of Colorado, Denver | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06975111 (opens in a new tab)Primary source | System checked NPHLA updated |
| AMPLIFY-2: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT07881458Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: eloralintide and tirzepatide; Tirzepatide | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07881458 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) on the schedule set in the Source Registry: one broad search for obesity and incretin therapies (GLP-1, semaglutide, tirzepatide, retatrutide, orforglipron, amylin, cagrilintide, survodutide) and a separate search for each metabolic topic that has a trial query, such as retatrutide or orforglipron. Each study is stored with its registry fields exactly as published: title, phase, overall status, sponsor, conditions, interventions and the date of its last registry update.
When a study’s overall status changes, or results are first posted, the change is recorded with the date the pipeline detected it. This tracker lists studies on the Metabolic desk whose registered phase includes phase 2 or phase 3 (combined phase 2/3 studies included). Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch in phase 2 and phase 3 on the metabolic desk.
What does it cover?
Studies listed on ClinicalTrials.gov — from the United States and other countries — that match the search terms above, from the date tracking of each search began. Phase 2 and phase 3 only. Phase 1 and phase 4 studies, studies described with other terms and studies registered only in other registries are not included.
What are its limitations?
Registry records are maintained by trial sponsors and can lag events; the status shown is the sponsor’s registry status at the last check, not an assessment of the trial. Searches can include studies of these medicines for conditions other than obesity and can miss studies that use different terms. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry; the table reflects each completed check.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.